

THE US CANCER DIAGNOSTICS MARKET

Table of Contents

Introduction

Worldwide Market and Technology Overview

- A. Cancer Statistics and Etiology
 - 1. Bladder
 - 2. Breast
 - 3. Cervical
 - 4. Colon and Rectum
 - 5. Endometrial
 - 6. Esophagus
 - 7. Head and Neck
 - 8. Leukemia
 - 9. Lung
 - 10. Lymphoma
 - 11. Oral
 - 12. Ovarian
 - 13. Prostate
 - 14. Renal Cell Carcinoma
 - 15. Skin
 - 16. Stomach
 - 17. Uterine
- B. Major Current And Emerging Cancer Diagnostic Tests
 - 1. Introduction
 - 2. Tumor Marker Classification
 - 3. ACTH
 - 4. Alpha-Fetoprotein (AFP)
 - 5. Beta-2 Microglobulin
 - 6. CA 15-3/27.29
 - 7. CA 19-9
 - 8. CA-125
 - 9. Calcitonin
 - 10. Carcinoembrionic Antigen (CEA)
 - 11. Estrogen and Progesterone Receptors
 - 12. Ferritin
 - 13. Gastrin
 - 14. Human Chorionic Gonadotropin (HCG)
 - 15. Insulin
 - 16. Lymphocytes CD4/CD8

Table of Contents (continued)

17. *NSE*
18. *Occult Blood*
19. *PAP Smear/HPV*
20. *Prostatic Acid Phosphatase (PAP)*
21. *Prostate-Specific Antigen (PSA)*
22. *Squamous Cell Carcinoma Antigen (SCC)*
23. *TdT*
24. *Thyroglobulin*
25. *Tissue Polypeptide Antigen (TPA)*
26. *Biochemical Tumor Markers*
 - *ADA*
 - *B-Protein*
 - *PNP*
 - *5'-Nucleotidase*
27. *Oncogenes*
 - *Abl/abl-bcr*
 - *AIB1*
 - *APC*
 - *BTA 26*
 - *BCL-2*
 - *BCR-ABL*
 - *B-raf*
 - *BRCA*
 - *CD44*
 - *CDK*
 - *C-abl*
 - *C-fos*
 - *C-myb*
 - *C-myc*
 - *CYCD1*
 - *CYP-17*
 - *DPC*
 - *E-myc*
 - *Erb-B*
 - *HER-2/neu*
 - *HPC1*
 - *HSTF*
 - *L-myc*
 - *MET*
 - *MSH*
 - *NEU*
 - *N-myc*

Table of Contents (continued)

- *N-telopeptide*
- *PCA3*
- *PIK3CA*
- *PTI-1*
- *P10*
- *P40*
- *P51*
- *P53*
- *Ras*
- *Reg*
- *RET*
- *sFas*
- *Sis*
- *Src*

28. *Polypeptide Growth Factors*

- *Basic Fibroblast Growth Factor*
- *Beta-TGF*
- *Cachectin (TNT)*
- *Calmodulin*
- *ECFR*
- *Nerve Growth Factor (NGF)*
- *Epidermal Growth Factor (EGF)*
- *Ornithine Decarboxylase*
- *Transferrin*
- *Transforming Growth Factor-Alpha*

29. *Ectopic Hormones*

30. *Colony Stimulating Factors*

31. *Lymphokines*

- *Alpha-Interferon*
- *B Cell Growth Factors*
- *B Cell Growth Factor (BCGF)*
- *Gamma-Interferon*
- *Interleukin-1 (IL-1)*
- *Macrophage Activating Factor*

32. *Immunohistochemical Stains*

33. *Emerging Tumor Markers*

- *N-Acetylglucosamine*
- *Actin*
- *Alpha-Actin*
- *Angiogenin*
- *Angiostatin*
- *Antineuronal Antibodies*

Table of Contents (continued)

- 7B2
- B72.3
- B-Protein
- Bax
- BCD-F9
- BLCA-4
- Blood Group Antigens A,B,H
- BTA
- CA 50
- CA 72-4/TAG-72
- CA 195
- CA-242
- CA-549
- Cadherin
- CAM 26
- CAR-3
- CD105
- Cathepsin-D
- Chromogranin A and B
- Cluster 1 Antigen
- Cluster-5/5A Antigen
- COX Antigen
- CTA
- CU18
- Cyclin
- DR-70
- DU-PAN-2
- Endometrial Bleeding Associated Factor
- Endostatin
- Epithelial Membrane Antigen
- FDP
- Feulgen Hydrolysis
- Fibronectin
- FSH
- (1->3)-L-fucosyltransferase
- Gastrin-Releasing Peptide (GRP)
- GDCFP-15
- Glucagon
- Glycoamines
- H23
- HAAH
- hk3

Table of Contents (continued)

- HPA
- HSP27
- Human Carcinoma Antigen
- ICAM
- Intermediate Filaments
 - Cytokeratins/CK18/Cyfra 21-1
 - Desmin
 - Gliofibrillary Acid Protein
 - Neurofilaments
 - Vimentin
- KA 93
- Kallikrein
- Kinases
- KP16D3
- LAI
- Leukocyte Common Antigen
- Lewis Antigens
- Lysophosphatidic Acid (LPA)
- Ma 695/Ma 552
- MABDF3
- MAG
- ME1
- Minactivin
- MN/CA9
- MSA
- Mucin Cancer Antigen (MCA)
- Multiple Tumor Suppressor 1
- Myosin
- NEA-130
- NMP22
- Nucleolar
- OA-519
- Opioid Peptides
- P-glycoprotein
- Pancreatic Oncofetal Antigen (POA)
- Parathyroid Hormone
- Placental Lactogen
- PR92
- Proliferative Index, Ki-67
- Px
- RB Inactivation/Deletion

Table of Contents (continued)

- Ret
- S-100 Protein
- SCCL 175
- Selectin
- Serotonin
- Sialic Acid
- Sialyl SSEA-1/SLX
- SN10
- Somatostatin
- TA-90
- TABA
- Tachykinin
- TAG 12
- TPS
- Troponin
- Tubulin
- VCAM
- VEGF
- Villen
- White Blood Cell Markers

C. Instrumentation Review And
Market Needs

- Abbott Architect
- Abbott AxSYM
- Abbott IMx
- Amersham Amerlite
- Bayer ACS: 180
- Bayer ADVIA Centaur
- Bayer Immuno 1
- Beckman Coulter Access
- bioMerieux Vidas Series
- Biotrol System 7000
- Dade Behring Dimension
- DPC Immulite
- DiaSorin ETI-Max
- Ortho-Clinical Diagnostics Vitros
- Olympus PK Series
- Roche Elecsys
- Roche Modular
- Tosoh AIA Series

Table of Contents (continued)

- D. *Current and Emerging Technologies*
 - 1. *Monoclonal and Polyclonal Antibodies*
 - 2. *Immunoassays*
 - a. *Technological Principle*
 - b. *Radioimmunoassay (RIA)*
 - c. *Enzyme Immunoassays (EIA)*
 - *Overview*
 - *ELISA*
 - *Immunofiltration*
 - *Particle-Membrane Capture Immunoassay*
 - *Enzyme Amplification*
 - d. *Fluorescent Immunoassays*
 - e. *Luminescence*
 - *Chemiluminescence*
 - *Bioluminescence*
 - 3. *Molecular Diagnostics*
 - a. *Technology Overview*
 - b. *Amplification Methods*
 - *PCR*
 - *DAP-PCR*
 - *Immuno-PCR*
 - *QC-PCR*
 - *CAR*
 - *DNA*
 - *HPA*
 - *LCR*
 - *NASBA*
 - *QBR*
 - *SDA*
 - *3 SR, and others*
 - 4. *Biochips/Microarrays*
 - 5. *Chromosome Analysis*
 - a. *Chronic Myelogenous Leukemia (CML)*
 - b. *Acute Myeloid Leukemia (AML)*
 - c. *Acute Lymphoblastic Leukemia (ALL)*
 - d. *Malignant Lymphomas*
 - Lymphoid Malignancies*
 - e. *Chronic Lymphocytic Leukemia (CLL)*
 - f. *Solid Cancers*
 - g. *Chromosomal Translocation and Oncogenes*

Table of Contents (continued)

- 6. *Microcomputers and Automation*
- 7. *Artificial Intelligence*
- 8. *Flow Cytometry*
- 9. *Biosensors*
- E. *Competing/Complementing Technologies*
 - 1. *CT*
 - 2. *MRI*
 - 3. *NMR*
 - 4. *PET*
 - 5. *Photonics Spectroscopy*
- F. *Business Environment*
 - 1. *Worldwide Market Structure*
 - 2. *Worldwide Market Size and Growth*
- G. *Personal Testing*

U.S.A.

- A. *Executive Summary*
- B. *Business Environment*
 - 1. *Health Care Expenditures*
 - 2. *Cost Consciousness*
 - 3. *Reimbursement*
 - 4. *Industry Consolidation*
 - 5. *Managed Care*
 - a. *HMO*
 - b. *PPO*
 - 6. *Hospitals*
 - 7. *Admissions*
 - 8. *Length of Stay*
 - 9. *Industry Diversification*
 - 10. *Physician Demographics*
 - 11. *Population Aging*
 - a. *Chronic Illness*
 - b. *Disease Incidence*
 - c. *Susceptibility to Iatrogenesis*
 - d. *Multiple Illness Cases*
 - 12. *Laboratory Regulations*
 - 13. *FDA Reform*
- C. *Market Structure*
 - 1. *Centralized Testing*
 - a. *Hospitals*
 - b. *Commercial/Private Laboratories*

Table of Contents (continued)

- 2. POT/Decentralized Testing
 - a. Physician Offices/Group Practices
 - b. Cancer Clinics
 - c. Other Decentralized Testing Locations
- D. Market Size, Growth and Major Suppliers Sales, Instrument Placements and Market Shares

Major Product Development Opportunities

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- D. Auxiliary Products

Design Criteria for Decentralized Testing Products

Alternative Market Penetration Strategies

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies
 - 1. Marketing Approaches
 - 2. Product Complexity
 - 3. Customer Preference
 - 4. Established Suppliers
 - 5. Emerging Suppliers
 - 6. Major Types of Distributors
 - 7. Market Segmentation Factor

Potential Market Entry Barriers and Risks

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

Table of Contents (continued)

Competitive Profiles

- Abbott
- AdnaGen
- Agensys
- Altana
- Ambrilia Biopharma
- AMDL
- BD
- Beckman Coulter
- Biofield
- Biomedical Diagnostics
- bioMerieux
- Bio-Rad
- Biotrol/B. Braun
- CeMines
- Cepheid
- CIS/BIO
- Cliniq
- Correlogic Systems
- Cytyc
- Daiichi
- DakoCytomation
- diaDexus
- DiagnoCure
- Diagnostic Systems
- Dianon
- DiaSorin
- Digene
- Eiken
- Enterix
- Enzo Biochem
- Epigenomics
- Exact Sciences
- Fujirebio
- Gen-Probe
- Gene Logic
- Green Cross
- Grifols-Quest
- Guided Therapeutics
- Ibex Technologies
- Immunicon
- Ipsogen

Table of Contents (continued)

- *Kyowa Medex*
- *Matritech*
- *Molecular Diagnostics*
- *Myriad Genetics*
- *Nippon Flour Mills*
- *OncoLab*
- *Ortho-Clinical Diagnostics*
- *Panacea Pharmaceuticals*
- *Polartechnics*
- *Polymedco*
- *PreMD*
- *Quest Diagnostics Nichols Institute*
- *Roche Diagnostics*
- *Scantibodies*
- *Siemens*
- *Targeted Diagnostics*
- *Tosoh*
- *Trylon*
- *Wako Chemicals*
- *Worldwide Medical*
- *Zila*

Appendixes

- Appendix I: Major Companies Developing or Marketing Cancer Diagnostic Reagents and Instruments*
- Appendix II: Major Universities and Research Centers Developing Cancer Diagnostic Technology and Applications*
- Appendix III: Assumed Currency Exchange Rates*

List of Tables

Tumor Marker Classification

*Major Companies Developing or Marketing
ACTH Tests*

*Major Companies Developing or Marketing
AFP Tests*

*Major Companies Developing or Marketing
Beta-2 Microglobulin Tests*

*Major Companies Developing or Marketing
CA 15-3/27.29 Tests*

*Major Companies Developing or Marketing
CA 19-9 Tests*

*Major Companies Developing or Marketing
CA 125 Tests*

*Major Companies Developing or Marketing
Calcitonin Tests*

*Major Companies Developing or Marketing
CEA Tests*

*Major Companies Developing or Marketing
Estrogen Receptor Tests*

*Major Companies Developing or Marketing
Progesterone Receptor Tests*

*Major Companies Developing or Marketing
Ferritin Tests*

*Major Companies Developing or Marketing
Gastrin Tests*

*Major Companies Developing or Marketing
HCG Tests*

List of Tables (continued)

*Major Companies Developing or Marketing
Insulin Tests*

*Major Companies Developing or Marketing
NSE Tests*

*Major Companies Developing or Marketing
Occult Blood Tests*

*Major Companies Developing or Marketing
PAP Smear/HPV Tests*

*Major Companies Developing or Marketing
PAP Tests*

*Major Companies Developing or Marketing
PSA Tests*

*Major Companies Developing or Marketing
Lymphocyte Subclassification Tests*

*Biochemical Markers Potential Applications
In Cancer Diagnosis*

*Oncogenes Potential Applications
In Cancer Diagnosis*

*Major Companies Developing or Marketing
Oncogene Tests*

*Growth Factors Potential Applications
In Cancer Diagnosis*

*Colony Stimulating Factors Potential
Applications in Cancer Diagnosis*

*Lymphokines Potential Applications
In Cancer Diagnosis*

List of Tables (continued)

*Immunohistochemical Stains Potential
Applications in Cancer Diagnosis*

*Executive Summary Table: U.S., Total Tumor
Marker Test Volume and Sales Forecast by
Market Segment*

U.S., Estimated New Cancer Cases and Deaths

*U.S., Estimated Cancer Death Rates
Per 100,000 Population*

*U.S., Laboratories Performing Tumor
Marker Tests by Market Segment*

*U.S., Hospital Laboratories Performing
Tumor Marker Tests by Bed Size*

*U.S., Commercial/Private Laboratories
Performing Tumor Marker Tests by
Annual Test Volume*

*U.S., Physician Office Laboratories
Performing Tumor Marker Tests by
Practice Size*

*U.S., Total Tumor Marker Test Volume
Forecast by Market Segment-201*

*U.S., All Market Segments Major
Tumor Marker Test Volume Forecast*

*U.S., Hospital Laboratories Major Tumor
Marker Test Volume Forecast by Test*

*U.S., Commercial/Private Laboratories
Major Tumor Marker Test Volume
Forecast*

List of Tables (continued)

*U.S., Physician Offices/Group Practices
Major Tumor Marker Test Volume Forecast*

*U.S., Cancer Clinics Major Tumor
Marker Test Volume Forecast by Test*

*U.S., Total Tumor Marker Sales
Forecast by Market Segment*

*U.S., All Market Segment Major Tumor
Marker Sales Forecast by Test*

*U.S., Hospital Laboratories Major Tumor
Marker Sales Forecast by Test*

*U.S., Commercial/Private Laboratories
Major Tumor Marker Sales Forecast by
Test*

*U.S., Physician Offices/Group Practices
Major Tumor Marker Sales Forecast by
Test*

*U.S., Cancer Clinics Major Tumor
Marker Sales Forecast by Test*

*U.S., ACTH Test Volume and Diagnostics
Sales Forecast by Market Segment*

*U.S., AFP Test Volume and Diagnostics
Sales Forecast by Market Segment*

*U.S., Beta-2 Microglobulin Test Volume and
Diagnostics Sales Forecast by Market
Segment*

*U.S., CA 15-3/27.29 Test Volume and
Diagnostics Sales Forecast by Market
Segment*

List of Tables (continued)

*U.S., CA 19-9 Test Volume and Diagnostics
Sales Forecast by Market Segment*

*U.S., CA-125 Test Volume and Diagnostics
Sales Forecast by Market Segment*

*U.S., Calcitonin Test Volume and
Diagnostics Sales Forecast by Market
Segment*

*U.S., Cathepsin Test Volume and Diagnostics
Sales Forecast by Market Segment*

*U.S., CEA Test Volume and Diagnostics
Sales by Market Segment*

*U.S., Chromogranin Test Volume and
Diagnostics Sales Forecast by Market
Segment*

*U.S., Colon-specific Antigen Test Volume and
Diagnostics Sales Forecast by Market
Segment*

*U.S., Cytokeratins Test Volume and
Diagnostics Sales Forecast by Market
Segment*

*U.S., Estrogen Receptor Test Volume and
Diagnostics Sales Forecast by Market
Segment*

*U.S., Ferritin Test Volume and Diagnostics
Sales Forecast by Market Segment*

*U.S., Gastrin Test Volume and Diagnostics
Sales Forecast by Market Segment*

*U.S., HCG Test Volume and Diagnostics
Sales Forecast by Market Segment*

List of Tables (continued)

*U.S., Insulin Test Volume and Diagnostics
Sales Forecast by Market Segment*

*U.S., Interferons Test Volume and
Diagnostics Sales Forecast by Market
Segment*

*U.S., Interleukins Test Volume and
Diagnostics Sales Forecast by Market
Segment*

*U.S., Lymphocyte Subtyping Test Volume and
Diagnostics Sales Forecast by Market
Segment*

*U.S., NSE Test Volume and Diagnostics
Sales Forecast by Market Segment*

*U.S., Nucleolar Test Volume and Diagnostics
Sales Forecast by Market Segment*

*U.S., Occult Blood Test Volume and
Diagnostics Sales Forecast by Market
Segment*

*U.S., Oncogenes Test Volume and Diagnostics
Sales Forecast by Market Segment*

*U.S., Pancreatic Oncofetal Antigen
Test Volume and Diagnostics Sales Forecast
by Market Segment*

*U.S., PAP Smear Test Volume and Diagnostics
Sales Forecast by Market Segment*

*U.S., Parathyroid Hormone
Test Volume and Diagnostics Sales Forecast
by Market Segment*

*U.S., Progesterone Receptor Test Volume
And Diagnostics Sales Forecast by Market
Segment*

List of Tables (continued)

*U.S., PAP Test Volume and Diagnostics
Sales Forecast by Market Segment*

*U.S., PSA Test Volume and Diagnostics
Sales Forecast by Market Segment*

*U.S., S-100 Protein Test Volume and
Diagnostics Sales Forecast by Market
Segment*

*U.S., Serotonin Test Volume and Diagnostics
Sales Forecast by Market Segment*

*U.S., Sialic Acid Test Volume and Diagnostics
Sales Forecast by Market Segment*

*U.S., Squamous Cell Carcinoma Antigen
Test Volume and Diagnostics
Sales Forecast by Market Segment*

*U.S., TDT Test Volume and Diagnostics
Sales Forecast by Market Segment*

*U.S., Thymidine Kinase
Test Volume and Diagnostics
Sales Forecast by Market Segment*

*U.S., Thyroglobulin Test
Volume and Diagnostics
Sales Forecast by Market Segment*

*U.S., TPA Test Volume and Diagnostics
Sales Forecast by Market Segment*

*U.S., Total Tumor Marker Sales
By Major Supplier*

*U.S., AFP Testing Market Diagnostics
Sales by Major Supplier*

List of Tables (continued)

*U.S., CA 125 Testing Market Diagnostics
Sales by Major Supplier*

*U.S., CA 15-3/27.29 Testing Market
Diagnostics Sales by Major Supplier*

*U.S., CEA Testing Market Diagnostics
Sales by Major Supplier*

*U.S., Ferritin Testing Market
Diagnostics Sales by Major Supplier*

*U.S., HCG Testing Market
Diagnostics Sales by Major Supplier*

*U.S., Insulin Testing Market
Diagnostics Sales by Major Supplier*

*U.S., PAP Testing Market Diagnostics
Sales by Major Supplier*

*U.S., PSA Testing Market Diagnostics
Sales by Major Supplier*

*U.S., Tumor Marker Testing Instrumentation
Major Systems Estimated Placements and
Installed Base by Supplier and Model*